Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
19 January 2024 - 5:15PM
Cresemba® sales in Latin America trigger first sales milestone
payment to Basilea
Allschwil, Switzerland, January 19, 2024
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a
commercial-stage biopharmaceutical company committed to meeting the
needs of patients with severe bacterial and fungal infections,
announced today that the sales of the antifungal Cresemba®
(isavuconazole) in 2023 by its partner Knight Therapeutics Inc.
(“Knight”, TSX: GUD) in Latin America exceeded the threshold
triggering the first sales milestone payment for this region.
David Veitch, Chief Executive Officer, said: “We are very
pleased with the commercial progress that Knight has made with
Cresemba, which has now triggered the first sales milestone payment
from Knight for Latin America. The continued growth confirms that
Cresemba is serving a high medical need around the world.”
By year-end 2023, Cresemba was marketed in more than 70
countries, including the United States, most EU member states,
China, Japan and countries in Latin America. According to the
latest available market data, total global in-market sales of
Cresemba in the twelve-month period between October 2022 and
September 2023 amounted to USD 445 million, a 22 percent
growth year-on-year.1
About Cresemba®
(isavuconazole)
Isavuconazole, is an intravenous (i.v.) and oral azole
antifungal, commercialized under the trade name Cresemba®. Basilea
has entered into several license and distribution agreements for
isavuconazole covering approximately 115 countries. In the
27 European Union member states, as well as in Iceland,
Liechtenstein, Norway and the U.K., isavuconazole is approved for
the treatment of adult patients with invasive aspergillosis and for
adult patients with mucormycosis for whom amphotericin B is
inappropriate.2 In the United States (US), Cresemba for injection
is indicated for the treatment of invasive aspergillosis and
invasive mucormycosis in adults and pediatric patients 1 year of
age and older and Cresemba capsules are indicated for the treatment
of adults and pediatric patients 6 years of age and older, who
weigh 16 kilograms and greater.3 Isavuconazole is also approved in
several additional countries in Europe and beyond, including Japan
and China.4 It has orphan drug designation in the US, Europe and
Australia for its approved indications.
About Basilea
Basilea is a commercial-stage biopharmaceutical company founded
in 2000 and headquartered in Switzerland. We are committed to
discovering, developing and commercializing innovative drugs to
meet the needs of patients with severe bacterial and fungal
infections. We have successfully launched two hospital brands,
Cresemba for the treatment of invasive fungal infections and
Zevtera for the treatment of bacterial infections. In addition, we
have preclinical and clinical anti-infective assets in our
portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN).
Please visit basilea.com.
Disclaimer
This communication expressly or implicitly contains certain
forward-looking statements, such as "believe", "assume", "expect",
"forecast", "project", "may", "could", "might", "will" or similar
expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its
business, including with respect to the progress, timing and
completion of research, development and clinical studies for
product candidates. Such statements involve certain known and
unknown risks, uncertainties and other factors, which could cause
the actual results, financial condition, performance or
achievements of Basilea Pharmaceutica Ltd, Allschwil to be
materially different from any future results, performance or
achievements expressed or implied by such forward-looking
statements. Basilea Pharmaceutica Ltd, Allschwil is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.
For further information, please contact:
Peer Nils Schröder, PhD Head of Corporate
Communications & Investor RelationsBasilea Pharmaceutica
International Ltd, Allschwil Hegenheimermattweg 167b4123
AllschwilSwitzerland |
Phone |
+41 61 606 1102 |
E-mail |
media_relations@basilea.cominvestor_relations@basilea.com |
This press release can be downloaded from www.basilea.com.
References
- IQVIA Analytics Link, September 2023. In-market sales reported
as moving annual total (MAT) in U.S. dollar.
- European Public Assessment Report (EPAR) Cresemba:
https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba [Accessed:
January 18, 2024]
- Cresemba US prescribing information:
https://www.astellas.us/docs/cresemba.pdf [Accessed: January
18, 2024]
- The registration status and approved indications may vary from
country to country.
Basilea Pharmaceutica (LSE:0QNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Basilea Pharmaceutica (LSE:0QNA)
Historical Stock Chart
From Apr 2023 to Apr 2024